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Background: Tau is a microtubule stabilizing protein and is mainly expressed in neurons. Tau aggregation into
oligomers and tangles is considered an important pathological event in tauopathies, such as frontotemporal
dementia (FTD) and Alzheimer’s disease (AD). Tauopathies are also associated with deficits in synaptic plasticity such
as long-term potentiation (LTP), but the specific role of tau in the manifestation of these deficiencies is not well-
understood. We examined long lasting forms of synaptic plasticity in JNPL3 (BL6) mice expressing mutant tau that
is identified in some inherited FTDs.
Results: We found that aged (>12 months) JNPL3 (BL6) mice exhibit enhanced hippocampal late-phase (L-LTP), while
young JNPL3 (BL6) mice (age 6 months) displayed normal L-LTP. This enhanced L-LTP in aged JNPL3 (BL6) mice was
rescued with the GABAAR agonist, zolpidem, suggesting a loss of GABAergic function. Indeed, we found that mutant
mice displayed a reduction in hippocampal GABAergic interneurons. Finally, we also found that expression of mutant tau
led to severe sensorimotor-gating and hippocampus-dependent memory deficits in the aged JNPL3 (BL6) mice.
Conclusions: We show for the first time that hippocampal GABAergic function is impaired by pathological tau protein,
leading to altered synaptic plasticity and severe memory deficits. Increased understanding of the molecular mechanisms
underlying the synaptic failure in AD and FTD is critical to identifying targets for therapies to restore cognitive deficiencies
associated with tauopathies.
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Tau is a microtubule binding protein, primarily expressed
in the central nervous system [1]. It is predominantly lo-
calized to axons, regulating the stability of axonal micro-
tubules [2,3]. Tau has also been identified in dendrites,
albeit at lower levels than in axons [4]. Tau is highly
soluble and its activity is regulated by phosphorylation at
specific sites (reviewed in [5]). In frontotemporal dementia
(FTD) and Alzheimer’s disease (AD), tau becomes
hyperphosphorylated, leading to an accumulation of tau in
the somatodendritic compartment that eventually forms a* Correspondence: Charles.Hoeffer@nyumc.org
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reproduction in any medium, provided the orneurofibrillary tangle (NFT). NFTs are thought to lead to
neuronal dysfunction and neuronal death [5]. However,
some recent evidence shows that NFTs are not toxic per
se, but instead soluble hyperphosphorylated tau protein,
present in early and late stages of disease, are the key
pathogenic species [6]. In both scenarios, tauopathy leads
to a loss of synapses and neurons with associated cognitive
and behavioral impairments [7,8].
Synaptic impairments in several AD mouse models
that express mutant amyloid precursor protein (APP)
[9-11] and hippocampal slices treated with Aβ oligomers
[12,13] have established the importance of Aβ pathology
in synaptic function in AD. Tau has been proposed as a
key mediator of Aβ-associated cellular and cognitive de-
fects [14,15] and Aβ-directed long-term potentiation
(LTP) deficits [16]. These findings may indicate that taul Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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directed effects. In support of this notion, a few pure
tauopathy models have been associated with aberrant
LTP [17-19]. However, these studies examined very tran-
sient forms of LTP and examined plasticity in young
mice, before the onset of tau pathology. Compared to
the significant effort made exploring Aβ-mediated effects
on synaptic function, much less is understood about the
role of pathological tau protein in synaptic deficits.
Recent studies have shown that neural network abnor-
malities in the form of circuit hyperexcitability either
precede or lead to AD. For example, the incidence of
epilepsy is increased in patients with AD, suggesting an
imbalance in excitation and inhibition [20-22]. Also, in
patients with AD and in aged individuals, amyloid
plaques are found distributed along networks displaying
abnormal activity [23,24]. Finally, tau might play an
important role in circuit hyperexcitability, since it was
found that mutant P301L tau expression resulted in
electrophysiological changes in cortical pyramidal neu-
rons [25]. These changes include a depolarized resting
membrane potential, increased depolarizing sag potential
and increased action potential firing rates, which are all
indications of hyperexcitability. Taken together, these
findings strongly support the notion that neuronal
network balance is disturbed in tauopathies, and one
possible mechanism that may lead to this imbalance is
impairment of inhibitory neurotransmission.
Inhibitory neurotransmission in the brain is largely me-
diated by γ-aminobutyric acid (GABA) acting through
GABA type A receptors (GABAAR)s and GABA type B re-
ceptors (GABABR)s. Changes in GABAergic transmission
are implicated in the regulation of all aspects of brain
function, since they are critical for maintaining the proper
balance of activity in the brain. Deficits in GABAAR-medi-
ated transmission are implicated in the etiology of epilepsy
[26], anxiety [27], mood disorders [28], aging, and AD
[29]. Loss of normal excitatory/inhibitory balance resulting
from dysregulation of GABAergic signaling may underlie
increased incidence of epileptic seizures in AD patients
[30]. These data suggest that AD-related cognitive impair-
ments are likely to be affected by GABAergic dysregulation.
In the present study we examined hippocampus-
dependent synaptic plasticity and behavior in aged JNPL3
(BL6) mice, a transgenic (Tg) mouse model expressing
human mutant P301L tau in a C57BL6 background. Using
several experimental approaches of electrophysiology,
histology and behavior modeling, we found that the
expression of pathological tau led to significant physio-
logical alterations and behavioral abnormalities in aged
JNPL3 (BL6) mice. We found a loss of GABAergic inter-
neurons leading to electrophysiological alterations, sen-
sorimotor deficits, and severe hippocampus-dependent
memory deficits.This work has the potential to provide valuable transla-
tional insight into AD treatments by validating how strategies
for GABAergic manipulation and tau immunoclearance may
restore synaptic function in the AD brain.
Materials and methods
Animals
JNPL3 (BL6) transgenic mice (Taconic, New York) were
backcrossed in a C57BL/6 background (>10 generations).
Age-matched control wild-type (WT) mice were pur-
chased from Taconic. Mice were maintained on a 12:12
hour L:D schedule with food and water available ad
libitum. Mice were tested at six, 12 or 18 months of age,
depending on the experiments. Procedures were ap-
proved by the New York University School of Medicine
Institutional Animal Care and Use Committee.
Brain fractionation protocol for Western blot analysis
Tau solubility was analyzed using a modified protocol from
[31-33]. Briefly frozen cortex sections were homogenized
without thawing in 5 X vol/wg of RIPA buffer (50 mM
Tris–HCl, pH 7.4; 1% Nonidet P-40; 0.25% Na-
deoxycholate; 150 mMNaCl; 1 mM EDTA; 1 mM PMSF; 1
mM Na3VO4; 1 mM NaF; Complete protease inhibitor
cocktail, Roche, IN, USA), with a mechanical homogenizer
(TH; Omni International, USA), and centrifuged at 20,000
X g for 20 min at 4°C. An aliquot of the supernatant
representing the total tau fraction was kept for protein
quantification and western blot analysis. The rest of
the supernatant was adjusted to 1% sarkosyl (N-
lauroylsarcosine), incubated for 30 min at room
temperature with constant rotating, and centrifuged at
100,000g for one hr at 20°C. After high speed centrifuga-
tion, the pellet was washed with 1% sarkosyl and centri-
fuged again at 100,000g for one h at 20°C. The post wash
pellet containing sarkosyl-insoluble, aggregated tau was
resuspended and analyzed by SDS-PAGE. Tau in the
sarkosyl pellet has been shown by immuno-electron mi-
croscopy to be filamentous [32], and it is synonymous with
that identified by immunohistochemistry in NFTs. All frac-
tions were diluted in O+ buffer (62.5 mM Tris–HCl, pH
6.8; 10% glycerol; 5% 2-mercaptoethanol; 2.3% SDS; 1 mM
EGTA; 1 mM EDTA; 1 mM PMSF; 1 mM Na3VO4; 1 mM
NaF; Complete protease inhibitor cocktail, Roche), a modi-
fied O buffer, boiled for 5 min, and kept at −20°C. Depend-
ing on the antibody used, 10 to 20 μg of protein were
analyzed by western blotting. Equal amount of protein
(BCA assay, Promega) was loaded and the samples were
electrophoresed on 10-12% SDS-PAGE gels and transferred
to nitrocellulose membranes. All blots were blocked (5%
nonfat milk and 0.1% Tween 20 in TBS) and then incubated
with various primary antibodies overnight. Subsequently,
the blots were washed and incubated for 2 h at room
temperature with peroxidase-conjugated, goat anti-rabbit
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ImmunoResearch). Immunoreactive bands were visualized
and analyzed by enhanced chemiluminescent reagent
(Pierce ECL, Thermo Scientific) using a Fujifilm LAS4000
imaging system and theMulti Gauge software (Fujifilm Life
Science). To compare the relative amount of tau protein,
the densities of the immuno-reactive bands corresponding
to phospho-tau were normalized and reported relative to
the amounts of total tau protein or α-tubulin.Electrophysiology
Transverse hippocampal slices (400 μm) were prepared
from one hemisphere of age-matched mice (12–18 months
or 6–7 months of age) using a vibratome (from part of the
cohort, the other hemisphere was used to perform immu-
nostaining or in situ hybridization, see below). Slices were
maintained in oxygenated ACSF containing the following
(in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3,
25 D-glucose, 2 CaCl2, and 1 MgCl2 at room temperature.
For electrophysiology experiments, slices were transferred
to interface recording chambers (preheated to 30°C) per-
fused with oxygenated ACSF. Extracellular field EPSPs
(fEPSPs) were evoked by stimulation of Schaffer collateral
pathway afferents and were measured by recording in
stratum radiatum of area CA1. In order to determine the re-
sponse range for each hippocampal slice, the stimulus range
was divided into 10 arbitrary units. The slices were stimu-
lated at each level, and the fEPSP was recorded. In each re-
cording, the fiber volley amplitude was as a measure of the
input stimulation to the fEPSP. The range of input values
and their respective output values (measured as the fEPSP
slope) were plotted as a mean to characterize basal synaptic
transmission in transgenic and wild-type mice across all ex-
periments. Baseline responses were calculated using the
stimulation intensity that elicited 40-50% of the maximal
fEPSP response as determined by the input–output rela-
tionship. Paired-pulse facilitation (PPF), an assay of normal
presynaptic function, was induced with two stimuli of equal
intensity (same as baseline intensity) presented in rapid suc-
cession at variable interpulse intervals, ranging from 10 ms
to 300 ms. PPF was measured by examining the ratio of the
fEPSP slope in response to stimulus 2 and that of stimulus
1. Before LTP-inducing high-frequency stimulation (HFS),
stable baseline synaptic transmission was established for
20–30 min with a stimulus intensity of 40–50% of the max-
imum fEPSP. Stimulus intensity of the HFS was matched to
the intensity used in the baseline recordings. LTP was in-
duced by either one or four trains (2 min intertrain interval)
of 100 Hz HFS for 1 s. Data were collected and presented as
the average slope of the fEPSP from six individual traces
collected over 2 min and then normalized to baseline re-
cordings of fEPSPs. Hippocampal slices from Tg and WT
mice were prepared simultaneously and placed in achamber outfitted with dual-recording equipment, thereby
minimizing day-to-day variability in slice preparations and
recordings. For zolpidem treatment, slices were incubated
20 min prior to HFS with a subthreshold concentration of
zolpidem (1 μM). Student’s t-test, Repeated Measures
ANOVA or N-way ANOVA (where appropriate) were used
for electrophysiological data analysis with p < 0.05 as sig-
nificance criteria.
In situ hybridization
Brains (one hemisphere from mice also used for electro-
physiology) were fixed overnight in buffered 2% parafor-
maldehyde (PFA) at 4°C. Next day, hemispheres were
stored in 20% glycerol, 2% DMSO in phosphate buffer
(PB) until the brains were sliced as consecutive serial cor-
onal sections (5 series, 50 μm thickness). Brain sections
were stored in cryoprotectant (300 ml ethylene glycol, 550
ml PB, 300 g Sucrose, volume to 1000 ml with H2O;
pH7.2) until used. Serial brain sections were used to per-
form in situ hybridizations as previously described in [34].
Briefly, RNA probes were prepared using dioxygenin
(DIG) RNA labeling kits (Roche). Sections were postfixed
in 4% PFA for 10 min followed by a wash in phosphate-
buffered saline (PBS). Sections were treated with 1.5%
H2O2 in methanol and rinsed in PBS. Then, sections were
treated with 0.2 M HCl and washed in PBS. Proteinase K
(Roche) digestion (20 μg/mL in PBS) was carried out
followed by a wash in PBS, and the sections were refixed
for 5 min in 4% PFA and washed with PBS. The sections
were acetylated for 10 min (2.2 g triethanolamine hydro-
chloride (Sigma), 540 μL of 10 N NaOH (Fisher Scientific),
300 μL of acetic anhydride (Sigma) in 60 mL water) and
washed in PBS. RNA probes, prepared at a dilution of 2
μL/mL in hybridization solution (50% formamide, 10%
dextran sulfate, 1% 100× Denhart's, 250 μg/mL yeast
tRNA, 0.3 M NaCl, 20 mM Tris–HCl, pH8, 5 mM EDTA,
10 mM NaPO4, 1% sarkosyl), were incubated at 80°C for
2 min. Thereafter, 500 μL of the probe mix was applied to
the brain sections and incubated at 55°C overnight. The
next day, sections were subjected to high stringency wash
in pre-warmed 50% formamide, 2× SSC at 65°C. Next, the
sections were rinsed in RNase buffer (0.5 M NaCl, 10 mM
Tris–HCl, pH 7.5, 5 mM EDTA), followed by an RNaseA
(Roche) treatment (20 μg/mL in RNase buffer) for 30 min
and followed by a wash in RNase buffer, all at 37°C. The
high stringency washes were repeated twice for 20 min
each at 65°C, followed by a 15 min rinse in 2× SSC, then
0.1× SSC, both at 37°C. Sections were then washed in
Wash Buffer (WB, 100 mM maleic acid, 150 mM NaCl,
0.5% Tween-20) and blocked with Blocking Buffer (1%
Boehringer Manheim in WB) followed by incubation with
anti-DIG-POD antibody (Roche) overnight at 4°C. Next
day, slices were washed in WB and then incubated with
Blocking Buffer 2 (0.5% Casein, 150 mM NaCl, 100 mM
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sections, followed by washes in WB. Then sections were
incubated with Streptavidin – AP for 1h at room
temperature followed by 3 washes in WB and a wash in
NTMT buffer (100 mM NaCl, 100 mM Tris–HCl, pH 9.5,
50 mM MgCl2, 0.1% Tween-20). The sections were then
placed in a light-protected environment with approxi-
mately 400 μL of BM-purple AP substrate (Roche) until
satisfactory staining was achieved. Finally, the sections
were rinsed twice in PBS, coverslipped using Crystal
mount aqueous mounting media (Sigma) and images were
acquired using a Leica DM 5000B light microscope.
Using Image J software (National Institutes of Health),
regions of interests (ROI) were defined in all consecutive
slices of one mouse. The size of ROI varied to some extent
from anterior to posterior based on each individual slice.
General criteria for the CA1 ROI were determined by
boundaries starting at the CA2-CA1 border till the
subiculum-CA1 boundary, including the stratum oriens
and stratum radiatum. Within these ROIs, the number of
positive cells was counted. The number of positive cells
was corrected to the volume of the ROIs. All cell counts
were made by observers blind to genotype.
Immunohistochemistry
For fluorescent immunostaining to count number of SST
or PV positive cells from mice used for electrophysiology,
consecutive serial brain sections (50 μm thick) of freshly
fixed brain stored in cryoprotectant (see above), were
washed in PBS for 3× 10 min. For blocking and
permeabilization we used “staining buffer” containing 0.05
M Tris, 0.9% NaCl, 0.25% gelatin, and 0.5% Triton X-100,
pH 7.4. Primary antibodies, rabbit anti-somatostatin
(1:1000; Peninsula Laboratories/Bachem) and mouse anti-
parvalbumin (1:500; Sigma-Aldrich) were diluted in stain-
ing buffer and incubated overnight at 4°C. The next day,
the brain sections were washed in PBS and incubated with
donkey anti-mouse Cy3 antibody (1:200; Jackson
Immunoresearch) and donkey anti-rabbit Alexa 488 anti-
body (1:200; Jackson Immunoresearch), or with donkey
anti-mouse Alexa 488 (1:200; Jackson Immunoresearch)
and donkey anti-rabbit Cy3 antibody (1:200; Jackson
Immunoresearch) diluted in staining buffer with Hoechst
for one h at room temperature. Finally, the brain slices
were washed in PBS and mounted in Mowiol mounting
solution (Mowiol 4–88). In order to examine if patho-
logical tau was expressed in GABAergic interneurons, two
other aged JNPL3 (BL6) mice (age 13 months) were per-
fused with 0.9% saline, followed by perfusion of 4% para-
formaldehyde (PFA) in PBS. Brains were fixed overnight
in buffered 2% paraformaldehyde at 4°C. Next day, hemi-
spheres were stored in 20% glycerol, 2% DMSO in phos-
phate buffer (PB) until the brains were sliced as
consecutive serial coronal sections (5 series, 50 μmthickness). Brains slices were immunostained as described
above and incubated with rabbit anti-somatostatin
(1:1000; Peninsula Laboratories/Bachem) or rabbit anti-
parvalbumin (1:1000, Swant) and with mouse anti-PHF1
(1:500; gift from Dr. Peter Davies) or mouse anti-MC1
(1:100; gift from Dr. Peter Davies). Images of brains were
acquired using a Zeiss LSM510 confocal microscope. To
quantify the number of GABAergic interneurons per hip-
pocampal region, the complete hippocampus was imaged
using Zeiss Zen2009 software. Next, Z-stacked images
were stacked to a maximum intensity projections and
ROIs were defined in all consecutive slices of one mouse,
i.e. hippocampal CA1 and dentate gyrus (DG) in Image J.
ROI varied from posterior to anterior. General criteria for
the DG ROI were determined by the boundaries of the
granular layers. Criteria for the CA1 ROIs were
determined as described above. Within these ROIs, the
number of positive cells was counted. The average of all
positive cells was corrected to the volume of the ROIs.
For DAB staining, consecutive serial brain sections
(50 μm thickness) stored in cryoprotectant, were washed
in TBS (10 mM Tris, 140 mM NaCl, pH 7.4), then incu-
bated with 3% H2O2/0.25% Triton X-100 (Sigma) for 30
min and followed by incubation in 5% milk in TBS.
Brain slices were then incubated overnight with mouse
anti-PHF1 (1:1000) or mouse anti-MC1 (1:100) in 5% milk
in TBS. Slices were then washed in TBS +0.05% Triton-
X100 (TBS-T), incubated with goat anti-mouse-Biotin
(1:1000; M.O.M. kit, Vector laboratories) secondary anti-
body diluted in 20% Superblock (Pierce)/TBS-T for 2
hours, washed with TBS-T, and incubated with ABC reac-
tion (M.O.M. kit) in Superblock in TBS-T. Brain slices
were washed in 0.2 M sodium acetate and developed in
DAB + nickel ammonium sulfate (17mg of DAB, 1.25 g
Nickel ammonium sulfate in 50 ml of 0.2 M sodium acet-
ate and 0.3% H2O2). Slices were washed in sodium acetate
and TBS and mounted. Images of brains were acquired
using a Leica DM 5000B light microscope.Biotin surface labeling
Biotin surface labeling was performed as described in
[35]. Briefly, hippocampal slices were generated as de-
scribed for electrophysiology. Slices were maintained in
oxygenated ACSF containing the following (in mM):
125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 25 D-
glucose, 2 CaCl2, and 1 MgCl2 at 32°C for at least 1 h to
recover. Then slices were treated with 0.5 mg/ml Sulfo-
NHS-SS-biotin (Pierce) for 45 min on ice to label sur-
face proteins. Slices were then washed in Tris-ACSF
(25mM Tris pH 7.2 + ACSF). Slices were snap frozen
and lysed in homogenization buffer (in mM: 40 HEPES
pH 7.5, 150 NaCl, 10 pyrophosphate, 10 glycerophos-
phate, 1 EDTA) containing protease inhibitor and
Levenga et al. Acta Neuropathologica Communications 2013, 1:34 Page 5 of 14
http://www.actaneurocomms.org/content/1/1/34phosphatase inhibitor cocktail II and III (Sigma). Ho-
mogenates were cleared by centrifugation at 13000 rpm
for 10 min at 4°C. Then samples were run on a SDS-
page gel and immunoblotted against GABAAR alpha1
(1:1000, Neuromab), GABAAbeta2/beta3 (1:1000, Up-
state) and GAPDH (1:10000, Cell Signaling).
Behavioral studies
Contextual fear conditioning
Tg and control mice were tested at the age of 5–6 or 12–
13 months. Apparatus: Mice were trained and tested using
the FreezeFrame system (Coulbourn Instruments). For
training, mouse test cages equipped with stainless-steel
shocking grids were connected to a precision feedback
current-regulated shocker (Coulbourn Instruments). Each
test cage was contained in a sound-attenuating enclosure
(Coulbourn Instruments). Behavior was recorded using
low-light video cameras. Stimulus presentation was auto-
mated using Actimetrics FreezeFrame software version 2.2
(Coulbourn Instruments). All equipment was thoroughly
cleaned with water followed by isopropanol between ses-
sions. Fear conditioning: Mice were habituated for 2 min
on a shocking grid (context: shocking floor grids, vanilla
scent). Fear conditioning was conducted with three 2 s,
0.5-mA footshocks (US) separated by 30 s. After condition-
ing, mice were returned to their home cages. Fear memory:
Mice were retested in the training context (shocking grid,
vanilla scent) 1 h 24 h and 7 days after training. Freezing
behavior was measured using FreezeFrame (Coulbourn In-
struments). Student’s t-test was used to analyze the data
with p<0.05 as significant criteria.
Prepulse inhibition (PPI)
PPI test was used to study sensorimotor gating. Tg and
control mice were tested at the age of 5–6 or 12–13
months. The testing apparatus of a startle response sys-
tem was contained in a sound attenuating chamber cali-
brated for responses from mice that are 20–35 g in
weight (San Diego Instruments, San Diego, USA). Each
mouse was placed in a clear, cylindrical holding tube
within a sound-attenuating chamber and habituated for
4 min immediately prior to testing. The test started with
5 startle pulses of 120 dB to measure startle responses.
This was followed by 5 blocks of randomized trials: no
stimulus, startle stimulus (120 dB), 72 dB prepulse+120
dB startle, 84 dB prepulse+120 dB startle, 90 dB
prepulse+120 dB startle. The test was finalized by 5
startle pulses of 120 dB to measure habituation. The
prepulses were presented 100 ms before startle stimulus.
The inter-block interval ranged from 6–20 s. All tests
were performed at the same time of day following identi-
cal habituation periods. Mice failing to demonstrate
acoustic startle response at 2,5× baseline were excluded
as hearing impaired. Responses were detected as changeswithin the holding tube. Student’s t-test was used to
analyze the data with p<0.05 as significant criteria.
Hotplate
The hotplate test was used to determine any differences
in nociceptive responses. Mice were placed on a hotplate
preheated to 50°C (Columbus Instruments). The animal
was observed and the time for the animal to lift one of
its hind paws was recorded. The mice were then imme-
diately removed from the hotplate and placed back in
their cage. The hind paw is used to determine noci-
ception because lifting the front paws is also normal
exploratory behavior. Student’s t-test was used to analyze
the data with p<0.05 as significant criteria.
Results
Tau pathology is evident in aged JNPL3 (BL6) mice
JNPL3 mice, originally generated in a mixed genetic
background, develop severe pathological phenotypes,
such as neurofibrillary tangles [36]. In our study, we
used JNPL3 mice in a C57BL/6 background JNPL3
(BL6) (young: 5–6 months or aged: 12–18 months). To
determine if markers of pathological tau were present in
aged mice, we examined levels of total tau and phos-
phorylated tau in the cortex of JNPL3 (BL6) and age-
matched C57BL/6 wild-type (WT) control mice. We
found that the soluble protein fraction (low speed super-
natant) derived from Tg mice showed increased total tau
levels compared to WT mice (Figure 1a). In addition,
early and late-stage pathological phosphorylation sites of
tau, recognized by CP13, AT180, and PHF1 antibodies,
were significantly increased in the Tg mice (Figure 1a).
Tau protein levels in the sarkosyl pellet, which contains
insoluble tau aggregates, were also increased in Tg mice
(Figure 1b). Next we analyzed brain tissue from aged Tg
mice with the pathological-tau antibodies MC1 and PHF1.
MC1 immunostaining, an early-stage conformational tau
pathology marker, was found throughout the brain of Tg
mice, including in the molecular layer of the hippocampus
(Figure 1c). PHF1 staining, a late-stage phospho-tau path-
ology marker, also showed staining in Tg mice but was less
abundant than MC1 staining (Figure 1c). In WT mice, no
positive cells were identified (Additional file 1: Figure S1).
Combined these data clearly demonstrate that tau path-
ology is present in the aged JNPL3 (BL6) mice used for
this study.
Altered hippocampal LTP in aged JNPL3 (BL6) mice
Having verified tau pathology in aged Tg mice, we next
examined synaptic plasticity in the CA3-CA1 circuit in
hippocampal slices from Tg and WT animals. Late phase-
LTP (L-LTP) was significantly enhanced in aged Tg mice
compared to age-matched WT mice (Figure 2a, 2b). An
examination of several basal synaptic functions such as
aAT180















































































Figure 1 Aged JNPL3 (BL6) mice show increased tau pathology in the cortex and hippocampus. (a) Western blot analysis of total tau
levels and phospho-tau status in low speed supernatant (LSS) fractions. Total tau levels were significantly increased in Tg mice compared to
age-matched WT mice (n=14 per group, t26=4.616, ***P=0.0002). Early-stage pathological phospho-tau markers, AT180 and CP13, were also
significantly increased in cortical tissue from Tg mice (AT180: t26=3.674, *P=0.0011; CP13: t26=2.156, *P=0.0405). Immunoblotting with the PHF1
antibody showed a significant shift in the banding pattern from 50 kd to 53 kd in Tg mice when compared to WT controls (t26=2.527, *P=0.0179).
(b) Levels of insoluble sarkosyl pellet tau normalized to LSS total tau are increased in Tg mice compared to controls (t26=2.215, *P=0.0357). (c) Tg
mice showed positive immunostaining with pathological-tau MC1 and PHF1 antibodies. Both antibodies showed staining in the CA1 of JNPL3
(BL6) mice, although to a lesser extent for the PHF1 than MC1 antibody. Inset is higher magnification of the highlighted area. Since brains were
fixed with paraformaldehyde without perfusing, blood vessel staining was also present (DG=dentate gyrus, CA1= hippocampal area CA1; Scale
bar = 200 μm). Data presented as mean + SEM.
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early phase-LTP revealed no difference between Tg and
WT mice (Additional file 2: Figure S2). The L-LTP en-
hancement was age-dependent, as no effect was observed
in younger (6 months old) Tg mice compared to WT con-
trols (Additional file 3: Figure S3a). When we divided the
mice in three age groups of 6 months, 12 months and 18months, we found that enhanced L-LTP was detected
from 12 months of age (Additional file 3: Figure S3a, 3b
and 3c). Because primary neurons are not lost in aged
mice of this model [37], we hypothesized that inhibitory
GABAergic signaling was impaired in aged Tg mice lead-
ing to enhanced potentiation of the hippocampal CA3-
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Figure 2 Aged Tg mice exhibit altered synaptic plasticity which
can be rescued with zolpidem, a GABAAR agonist.
(a) Representative traces of field excitatory postsynaptic potentials
(fEPSP) in hippocampal slices from aged JNPL3 (BL6) and WT mice that
received four trains of high frequency stimulation (HFS) (gray = fEPSP
at baseline, black = fEPSP after HFS). (b) Late-phase long-term
potentiation (L-LTP) is enhanced in aged JNPL3 (BL6) mice compared
to WT controls (ANOVA: WT= 9 mice, 24 slices; Tg=12 mice, 28 slices,
F(1,50)=7.841, **p=0.007). (c) Representative traces of fEPSPs in slices
from aged JNPL3 (BL6) and WT mice treated with the GABAAR agonist
zolpidem and four trains of HFS (gray = fEPSP at baseline, black = fEPSP
after HFS). (d) Zolpidem (1 μM for 10’) rescued the enhanced L-LTP in
Tg mice while having no effect on L-LTP in WT slices (ANOVA: WT
zolpidem=6 mice, 11 slices, Tg zolpidem=7 mice, 17 slices, WT veh= 9
mice, 24 slices, Tg veh=9mice, 28 slices, F(1,78)=6.841, *p=0.011. Tukey
HSD comparison: Tg zolpidem vs. WT veh: p=0.971). Data presented as
mean ± SEM.
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we treated slices with a sub-threshold (no effect on basal
synaptic transmission) dose of the GABAA receptor
(GABAAR) agonist, zolpidem (1 μM) [38]. Zolpidem treat-
ment 10 min prior to stimulation rescued the enhanced L-
LTP in hippocampal slices from Tg mice, and importantly,had no effect on L-LTP in WT slices (Figure 2c,d). We also
found a significant positive correlation between the potenti-
ated fEPSP slope and the levels of phospho-tau markers
PHF1 (53 kD) and CP13 in the cortex (Additional file 4:
Figure S4), linking the severity of hippocampal dysfunction
to pathological tau expression. These findings support the
idea that the exaggerated synaptic plasticity in Tg mice re-
sults from reduced GABAergic function, perturbing normal
inhibitory-excitatory balance in the CA3-CA1 circuit.
Loss of hippocampal GABAergic interneurons
One explanation for our results is that JNPL3 (BL6) mice
have fewer surface GABAA receptors, reducing neuronal
responses to GABA. However, using biotin-surface label-
ing, we found that total levels and surface levels of several
GABAAR subunits (α1, β2, and β3) were unchanged in Tg
mice compared to WT mice (Additional file 5: Figure S5a,
5b). Another possibility is that hippocampal GABAergic
interneurons are reduced or lost in the hippocampus of
JNPL3 (BL6) mice. As shown in previous studies, the cell
body layer and the stratum oriens in the hippocampus
contain GABAergic interneurons that control excitation
[39,40]. To test this notion, we used in situ hybridization
with a GAD67 riboprobe to quantify the number of
GABAergic interneurons in the hippocampus. In agree-
ment with this idea, we found significantly fewer (~20%)
GAD67-positive cells in hippocampal area CA1 of Tg
mice compared to controls (Figure 3a, 3c). Several classes
of GABAergic interneurons have been identified using
molecularmarkers, including parvalbumin (PV) or som-
atostatin (SST) positive cells [41]. Because PV- and SST-
positive neurons represent the predominant populations
of GABAergic interneurons in the hippocampus [42], we
next determined whether the GABAergic interneurons re-
duced in Tg mice are represented by these two different
interneuronal types. We found that the number of both
PV and SST interneuron subtypes were significantly de-
creased (~20%) in area CA1 of Tg mice compared to WT
mice (Figure 3b, 3c). Additionally, we found significantly
fewer SST-positive neurons in the dentate gyrus (DG)
(Additional file 6: Figure S6). There was also a trend toward
fewer PV-positive cells in the DG, but it was not statistically
significant (Additional file 6: Figure S6). The combined re-
sults of these experiments indicate that hippocampal
GABAergic function in JNPL3 (BL6) mice is compromised
as a result of interneuronal cell loss, derived from the most
widely represented interneuronal classes in area CA1.
Pathological tau markers are expressed in GABAergic
interneurons
After finding that pathological tau staining is abundantly
present and that GABAergic interneurons are reduced
in the hippocampus of JNPL3 (BL6) mice we next exam-


















































Figure 3 Loss of GABAergic interneurons in hippocampal area
CA1. (a) In situ hybridization for the GABAergic marker, GAD67,
showed a significant reduction of GAD67-positive neurons in area
CA1 (Scale bar = 100 μm). (b) Fluorescent immunostaining against
parvalbumin (PV, Cy3) and somatostatin (SST, Cy2), counterstained
with Hoechst (Upper image are tiled images of 200× magnification,
lower panel 400× magnification). (c) Tg mice showed significantly
reduced numbers of GAD67-positive (WT=9 mice, 69 slices, Tg=8
mice, 60 slices, t15=2.143, *P=0.0490), SST-positive (WT=6 mice, 61
slices, Tg=7 mice, 61 slices t11=2.685, *P=0.0212), and PV-positive
(WT=7 mice, 61 slices, Tg=7 mice, 61 slices, t12=3.559, **P=0.0039)
neurons in CA1 region in series of brain slices. Data presented as
mean + SEM.
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do this, we perfused mice and stained fixed brain slices
for MC1 (an early pathological tau marker) and PV or
SST or for PHF1 (a late pathological tau marker) and PV
or SST. Strikingly, both GABAergic interneuron sub-
types co-localized with MC1 and PHF1 in the hippocam-
pus (Figure 4). We found that a subset of PV-positiveneurons in the CA1 region co-localized with MC1 and
PHF1 (Figure 4a, arrows). In the DG however, where
PV-positive neurons are less abundant, we did not find
PV-positive neurons that co-localized with either MC1
or PHF1 (Figure 4a, arrowheads). In contrast, we found
that SST-positive interneurons co-localized with MC1
and PHF1 staining in both the CA1 and dentate gyrus
(Figure 4b, arrows). These results show that pathological
tau markers are present in GABAergic interneurons,
which might promote interneuronal loss in the
hippocampus.
Hippocampus-dependent memory and sensorimotor
behavioral deficits
A characteristic feature of tauopathy is dementia, so next we
examined memory in aged JNPL3 (BL6) mice. Because we
found age-dependent deficits in hippocampal synaptic plasti-
city in these mice (Additional file 3: Figure S3), we assessed
both young and aged JNPL3 (BL6) mice in hippocampus-
dependent behavioral tasks. Several hippocampal-dependent
behavioral paradigms have been described including the
Morris Water Maze or Barnes Maze. However these tasks
are highly dependent on locomotor competency. Aged
JNPL3 mice in the mixed background develop severe motor
deficits [36], and while JNPL3 (BL6) mice are less impaired
(data not shown) they do exhibit some locomotor deficits.
Therefore, to reduce possible locomotor confounds, we de-
cided to test Tg mice and WTcontrols using the contextual
fear conditioning paradigm, a test that depends on hippo-
campal function but is less reliant on locomotor perfor-
mance. Mice were trained by placing them in a training
context and exposing them to a brief aversive unconditioned
stimulus (US, footshock). Then fear memory assessed by
freezing behavior was measured at three time points follow-
ing training (Figure 5a). Before the administration of the US,
no difference was detected in the freezing levels or baseline
exploratory locomotor activity between Tg and control mice
(Figure 5b). Although aged Tgmice displayed levels of acqui-
sition that was indistinguishable fromWTmice, they had se-
verely impaired short-term (1 h) and long-term memory (24
h and 7 days) (Figure 5b). The observed memory deficits
were not due to differences in nociception, as aged Tg and
WT mice displayed indistinguishable response curves in the
hot plate assay (Additional file 7: Figure S7). To determine if
the onset of this deficit was age-dependent, we also tested
younger mice (5–6 months of age). In contrast to aged Tg
mice, young Tgmice showed no contextual fear memory im-
pairment at 24 h (Figure 5b). We also tested prepulse inhib-
ition (PPI) of startle response, a behavioral assay dependent
on GABAergic function [43]. Consistent with the loss of the
GABAergic interneurons we observed, aged Tg mice had a
significantly impaired PPI response compared to WT con-
trols (Figure 5c), whereas young Tg and WT mice did not



























Figure 4 Colocalization of pathological tau, visualized with MC1 and PHF1 antibodies, in GABAergic interneurons in the hippocampus
of aged JNPL3 (BL6) mice. (a) Fluorescent immunostaining against parvalbumin (PV) and MC1 or PHF1 counterstained with Hoechst shows that
PV-positive GABAergic interneurons in the CA1 region express pathological tau. Higher magnification shows that not all neurons express
pathological-tau. (b) Immunostaining against somatostatin (SST) also shows colocalization with pathological tau with SST-positive GABAergic
interneurons. Interestingly, SST strongly colocalizes with pathological-tau in the hilus within the dentate gyrus (left panel; scale bar = 100 μm, right
panel; scale bar = 50 μm; arrows show GABAergic interneurons that co-localize with pathological tau markers, while arrowheads show GABAergic
interneurons that are not co-localizing with pathological tau markers).
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related pathological tau expression and may be related to
GABAergic dysregulation.
Discussion
In the current study we examined the effect of mutant tau
(P301L) on synaptic plasticity and behavior in aged JNPL3
mice in a C57BL/6 background, a mouse model for
tauopathy. We find that aged JNPL3 (BL6) mice show al-
tered hippocampal long-lasting LTP, behavioral abnormal-
ities such as deficits in both short and long term
contextual fear memory and reduced sensorimotor gating.Electrophysiological effects in JNPL3 (BL6) mice were
corrected by enhancing GABAergic function in the hippo-
campus. Consistent with a loss of GABAergic tone in Tg
mice, we found a reduced number of GABAergic interneu-
rons in area CA1 and dentate gyrus of the hippocampus.
Collectively, our data show for the first time that mutant
tau has toxic effects on GABAergic interneurons that pro-
gresses with age, leading to a loss of GABAergic function,
altered hippocampal synaptic plasticity, and impaired
memory and sensorigating in aged JNPL3 (BL6) mice.
Aged JNPL3 (BL6) mice show tau pathology consistent
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Figure 5 Over-expression of mutant tau impairs memory and
sensori-motor gating in an age dependent fashion (a) Schedule
of contextual fear conditioning testing (US=unconditioned
stimulus; memory tested at 1h, 24h and 7d delay). (b) Aged Tg
mice (age 12–13 months) showed impaired short-term (STM, 1 h)
(WT=11 mice, Tg=12 mice, t21=4.522, ***P=0.0002) and long-term
memory (LTM, 24h: t21=3.424, **P=0.0026; 7d: t21=4.283, ***P=0.0003)
when compared to WT mice. Young Tg mice (5–6 months) showed
normal memory when compared to age-matched WT controls (right
panel) (WT=9 mice, Tg=10 mice, t17=0.2793, P=0.7834). (c) Sensori-
motor gating was impaired in aged Tg mice (WT=17 mice, Tg=8
mice; 72dB: t23=0.2.130, *P=0.0441; 82dB: t23=2.532, *P=0.0186, 90dB:
t23=3.040, **P=0.0058). (d) Young Tg mice had normal sensorigating
when compared to young WT controls (WT=11 mice, Tg=11 mice;
72dB: t20=0.9115, P=0.3729; 82dB: t20=0.3533, P=0.7276, 90dB:
t20=0.1095, P=0.9139). Data are presented as mean ± SEM.; n.s.
not significant.
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region, especially in the molecular layer containing the den-
drites. The tau pathology we detect is, however, less robust
compared to JNPL3 mice in a mixed background [36]. This
is consistent with previous reports showing that JNPL3
(BL6) mice display a milder pathology than in a mixed back-
ground [44]. These findings, combined with ours, establish
again that the strain background is an important factor to
consider when studying mouse models of human disease.
Although the pathology we observe is milder, we think that
our study using this C57BL/6 background is very important
because it is more comparable to other AD mouse models
which use the same genetic background, for example TauRD
(pro and anti-aggregant) [19,45] and hAPPJ20 [46].
We found that expression of P301L tau in aged Tg mice
did not impair either basal synaptic transmission or transi-
ent forms of synaptic plasticity in the hippocampal Schaffer
collateral-area CA1 synaptic circuit. Although other reports
have shown alterations in short-term synaptic changes in
the hippocampus of AD mouse models [17,47], little was
known about long-lasting synaptic changes in aged JNPL3
(BL6) mice. Surprisingly, we found that L-LTP was en-
hanced in aged JNPL3 (BL6) mice (Figure 2a, Additional
file 3: Figure S3). This enhanced L-LTP was rescued
with treatment with zolpidem, a GABAA-receptor agonist
(Figure 2b). These results suggest that GABAergic function
is impaired in JNPL3 (BL6) mice. Indeed, supporting this
idea, we found that hippocampal GABAergic interneurons
in area CA1 were reduced in Tg mice (Figure 3). The L-LTP
rescue we observed with zolpidem treatment was not due
to over activation of GABAARs in the CA3-CA1 circuit, as
we titrated zolpidem to preclude detectable effects on the
L-LTP responses in WT slices. These results, combined
with our observations that I/O and PPF were essentially
normal in aged JNPL3 (BL6) mice, suggest that although
GABAergic interneuronal function is compromised, home-
ostatic compensation is able, at least partially, to maintain
essential circuit integrity in the aged JNPL3 (BL6) hippo-
campus. Functional deficits may only appear after the syn-
aptic circuit is challenged by activity above ‘nominal’ levels,
i.e. in response to behavioral experience or strong stimula-
tion. Future studies, using a more detailed examination of
single cell properties may reveal more subtle GABAergic
deficits not detectable using field recording approaches.
Additionally, it would be interesting to examine if these
mice have altered synaptic plasticity in other brain areas,
such as the dentate gyrus, where we also found a loss
of GABAergic interneurons and a co-localization of pa-
thological tau markers with GABAergic interneurons
(Additional file 6: Figure S6 and Additional file 4: Figure
S4). Additionally, other AD mouse models have shown
GABAergic interneuron and synaptic plasticity deficits in
the dentate gyrus [15,17,47,48]. Strikingly, aged JNPL3
(BL6) mice had severe memory deficits and impaired PPI
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involved in memory formation and sensorimotor gating.
Finding enhanced L-LTP and impaired behavioral perform-
ance may seem at first glance to be counterintuitive, but
other mouse models have shown enhanced LTP and
impaired memory [49-51]. Regardless, these results clearly
show that tau plays an important role, separate from Aβ, in
synaptic plasticity mechanisms.
Enhanced hippocampal LTP was also reported in very
young P301L mice (5–7 weeks of age), but only in the
dentate gyrus [17]. This group also showed that young
P301L mice had improved performance in the novel ob-
ject recognition assay. Since no tau pathology was present
at this age, the authors suggested that the over-expression
of tau resulted in improved trafficking of glutamate re-
ceptors, enhancing synaptic transmission and improving
memory. Alternative tau-dependent mechanisms may
regulate hippocampal synaptic plasticity in an age-
dependent fashion. Indeed, this may be likely as we found
that aged JNPL3 (BL6) mice with mild but detectable tau
pathology showed enhanced L-LTP but also severe mem-
ory deficits. Our data show the age-progressive loss of
GABAergic interneurons in area CA1, and these data
coupled with our zolpidem rescue data support the idea
that tau-mediated regulation of GABAergic function is
responsible for the enhanced L-LTP we detected. This no-
tion is further supported by the impaired PPI we observe,
a behavior that depends on GABAergic function, includ-
ing in the hippocampus [43,52]. Interestingly, co-staining
of pathological-tau antibodies with GABAergic inter-
neuron markers showed extensive co-localization in the
hippocampus (Figure 4). This finding indicates that patho-
logical tau is present in GABAergic interneurons. One ex-
planation could be that the prion promoter, which is used
to drive the transgene in JNPL3 (BL6), has greater activity
in GABAergic interneurons than in pyramidal cells,
resulting in greater expression in interneurons. However,
this is unlikely because the prion promoter has been
shown to be mainly active in the excitatory neurons within
the pyramidal layer in the hippocampus [53]. Therefore, it
might be that tau pathology in GABAergic interneurons is
developed from pathogenic isoforms contributed extracel-
lularly or that GABAergic neurons are particularly suscep-
tible to pathogenic tau. More research is necessary to
study the role of GABAergic interneurons in the develop-
ment of pathology and memory loss in AD.
In AD, it is known that cholinergic and glutamatergic
neurotransmission are disrupted, while inhibitory GABA
ergic neurotransmission, mediated by interneurons, is
thought to be well-conserved (reviewed in [54]). Re-
cently however, more evidence is emerging that also
GABAergic function is compromised. Limon et al.
showed that functional GABAA receptors are lost from
the brains of AD patients [30]. Furthermore, during thecourse of normal aging, hippocampal GABAergic interneu-
rons lose contact boutons [55], while this process is accel-
erated in hAPP mice (J20 line). An AD mouse model
expressing human amyloid precursor protein (hAPP) with
Swedish and Indiana mutations [55]. This suggests that the
excitation/inhibition balance during aging in hAPP (J20)
mice is more severely disrupted. Interestingly, aged hAPP
(J20) mice show no loss of GABAergic interneurons. An-
other AD mouse model, a triple transgenic mouse
(TauPS2APP) does show a loss of GABAergic interneurons
in the hippocampus of aged mutant mice compared to
WT mice [47]. Although this study did not examine per-
sistent forms of LTP in the CA3-CA1 circuit, they found
early phase-LTP enhancements in the dentate gyrus of
tauPS2APP mice. However, because this mouse model
carries three transgenes, it was not clear whether all or
one mutation contributed to the loss of GABAergic
interneurons. Our results suggest that expression of mu-
tant tau protein alone likely promotes the loss of hippo-
campal interneurons. Furthermore, several reports provide
evidence that the development of AD leads to hyper-
excitability, shown by the increased incidence of epileptic
activity in sporadic AD, which is particularly high in early-
onset autosomal-dominant AD [20,21,56,57]. One possible
explanation for this may be that GABAergic interneuronal
function, which is critical for maintaining excitatory/
inhibitory balance in the brain, is also impacted in
tauopathies like AD. AD mouse models provide experi-
mental support for this model of AD-related hyper-
excitability. For example, the hAPP (J20) mice, was shown
to have spontaneous epileptic activity, indicating network
hypersynchrony [46,55]. Interestingly, this network hyper-
synchrony in the hAPPJ20 model resulted from PV cell
dysfunction. Furthermore, in an earlier study the same re-
search group showed that reduction of tau in the hAPP
(J20) mouse model prevented behavioral deficits and
excitotoxicity [14]. Finally, the apoE4 knock-in (KI) mouse
model has impaired neurogenesis in the dentate gyrus
that was due to impaired presynaptic GABAergic input
and resulted in loss of GABAergic interneurons [15,48].
These mice also showed spatial learning and memory defi-
cits, which could be rescued with treatment with the
GABAAR potentiator pentobarbital [15]. Interestingly, the
GABAergic impairment was dependent on tau because
apoE4 KI mice in a tau knockout background did not ex-
hibit this phenotype [15]. These results support the idea
that tau plays an important role in the survival and func-
tion of GABAergic interneurons. To note, these findings
highlight the importance of tau in AD-related phenotypes
but do not address whether tau lesions on their own
manifest effects in AD-related synaptic plasticity and
hyperexcitability. Our present findings provide evidence
supporting a model directly implicating tau function in
the maintenance of balanced neuronal signaling networks.
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anti- or a pro-aggregant tau protein have been studied to
examine the effects of tau aggregation on synaptic plasticity
and behavior. While these models are not represented by
naturally occurring human mutations, they do provide
insight into the role of tau in synaptic plasticity. Pro-
aggregant tau resulted in impaired L-LTP in the CA3-CA1
hippocampal pathway, while an anti-aggregant tau model
showed enhanced CA1-LTP [19,58]. However, only the pro-
aggregant mice showed memory deficits, while the anti-
aggregant displayed normal memory, as assessed by Morris
water maze and the passive avoidance task. The Tg mice in
our study exhibit severe memory deficits and enhanced L-
LTP and express a mutant tau isoform with properties that
more closely align with pro-aggregant tau. While differences
in the effects on LTP between this study and our own may
be explained by the different models used, another intri-
guing possibility is that greater levels of tau aggregation may
affect other neuronal signaling pathways involved in the ex-
pression of L-LTP that are not impacted by the less severe
pathology present in our model. This finding also supports
the idea that tau conformation can have different effects on
synaptic function and memory, and tau mutations that pro-
mote pathological aggregation may impair hippocampal
function. This possibility may be useful to consider for de-
veloping therapeutic strategies that target tau aggregation.
In summary, this study provides valuable new evidence
for a role of tau independent of Aβ in AD-related synaptic
deficits. Our data support a model in which tau helps to
maintain proper network excitability through the regulation
of GABAergic function. ‘Normal’ cognition requires intact
neuromolecular pathways for the regulation of synaptic
plasticity. Altered synaptic function and memory deficits
are major hallmarks of dementia. Results from this study
suggest a promising therapeutic avenue for the treatment
of AD and FTD may be developing new drug regimens
based on removing existing or inhibiting the development
of tau pathology. However, effective application of this
strategy requires detailed knowledge about the effects of
tau pathology on cognition in preclinical model systems. By
identifying GABAergic function as a crucial pathway
influenced by the expression of pathological tau, we may
in the short-term be able to take advantage of several FDA
approved drugs regulating GABAergic function for use in
AD treatment. In the long-term, these studies may provide
new insight into the neuronal signaling pathways and
molecular targets that are regulated by tau to develop more
effective approaches for tauopathy treatment.
Additional files
Additional file 1: Figure S1. MC1 and PHF1 staining in the
hippocampus of WT mice. No specific MC1 or PHF1 staining is present in
the hippocampus of aged WT mice. Because the brains were usedsimultaneously for ex vivo slice electrophysiology, this hemisphere was
fixed without perfusing and blood vessel staining is visible. Inset is higher
magnification of the highlighted area. (DG=dentate gyrus,
CA1= hippocampal area CA1; scale bar = 200 μm).
Additional file 2: Figure S2. Basal synaptic transmission, paired-pulse
facilitation and E-LTP are not impaired in JNPL3 (BL6) mice. (a) Input
versus output plot indicates that aged (>12 month old) Tg and WT mice
have comparable fEPSP slopes evoked by increasing stimulation (WT = 21
slices, Tg = 20 slices, F(1,39)=0.703, p=0.407). (b) Tg mice exhibit normal
PPF compared to WT mice. The percent facilitation, determined by the ratio
of the second fEPSP to the second fEPSP, is shown as interpulse intervals from
10-300ms (WT= 6 mice, 20 slices, Tg=6 mice, 20 slices, F(1,38)=0.384, p=0.539).
(c) A single train of HFS evoked similar levels of -E-LTP in Tg and WT mice that
decayed to baseline after 80 minutes (WT= 3 mice, 5 slices; Tg= 3 mice, 6
slices, F(1,9)=0.369, p=0.559).
Additional file 3: Figure S3. Altered synaptic plasticity in JNPL3 (BL6)
mice is age dependent. (a) No difference in L-LTP between young JNPL3
(BL6) and WT mice (age 6–7 months) (WT= 5 mice, 8 slices, Tg=4 mice, 9
slices, F(1,15)=0.129, p=0.725). (b) L-LTP is found to be enhanced in JNPL3
(BL6) mice at 12 months (WT=3 mice, 10 slices; Tg=3 mice, 9 slices; F(1,17)
=7.384, p=0.015), and (c) at 18 months (WT=6 mice, 14 slices, Tg=9 mice,
19 slices, F(1-31)=2.193, *p=0.0359).
Additional file 4: Figure S4. fEPSP correlates with levels of pathological
tau. The level of pathological tau of the mice used for electrophysiology
was plotted against the fEPSP slope at 180 min after HFS induction.
There is a correlation between the amount of pathological tau levels and
the enhanced fEPSP slope suggesting a link between the amount of
pathological tau and altered synaptic plasticity.
Additional file 5: Figure S5. Surface labeling of JNPL3 (BL6) and WT
mice show no difference in the levels of GABAARα1 or GABAARß2,3
receptors (a) No differences in levels of GABAARα1, GABAARß2,3 or
synaptophysin are found in the total hippocampal lysates derived from
aged Tg mice compared to WT mice (n=4 each). (b)
Immunoprecipitation of biotin-labeled surface proteins show no
differences in number of surface GABAα1 receptor in aged Tg mice
compared to WT mice. GAPDH is also present on the extracellular matrix
[59] and can therefore be used as a loading control (n=4 each).
Additional file 6: Figure S6. Reduction of somatostatin (SST)-positive
GABAergic interneurons in the dentate gyrus (DG). Number of
SST-positive GABAergic interneurons is reduced in the DG of JNPL3 (BL6)
mice. Number of PV-positive GABAergic interneurons in the DG is also
reduced, although not statistically significant (SST; WT=6 mice, 54 slices,
Tg=7 mice, 59 slices t11=2.216, *P=0.0487 and PV; WT=7 mice, 54 slices,
Tg=7 mice, 59 slices, t12=1.916, P=0.0776).
Additional file 7: Figure S7. Nociception is not different in aged JNPL3
(BL6) compared to WT animals (age 13–14 months). To determine if
there is any difference in nociception between Tg and WT mice, we
tested their reflex on a hotplate preheated to 50°C. No difference in
nociception was found, suggesting that JNPL3 (BL6) are able to sense the
foot shocks given during the contextual fear memory test equally as well
as WT mice (WT=5 mice, Tg= 6 mice, t9=0.6690, p=0.52).
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